title: [Multicenter randomized controlled clinical study on levornidazole and sodium chloride injection in the treatment of pelvic anaerobic infections].
abstract: OBJECTIVE
  to evaluate clinical efficacy and safety of levornidazole in the treatment of pelvic anaerobic infections.
  
  
  METHODS
  a multicenter randomized controlled clinical study was conducted to evaluate clinical efficacy and safety of levornidazole. One hundred and fourty-three patients with pelvic anaerobic bacteria infection were classified into 70 cases treated by levornidazole in study group and 73 cases treated by Ornidazole in control group. Those patients in two groups were both administered at a dose of 0.5 g twice daily for 5 - 7 days. The rate of clinical efficacy, bacteria clearance and adverse effect were recorded and compared between two groups.
  
  
  RESULTS
  at the endpoint, the rate of clinical efficacy were 80% (56/70) in study group and 81% (59/73) in control group, which did not reach significant difference (P > 0.05). The rate of bacteria clearance were 97% (36/37) in study group and 92% (22/24) in control group, which also did not reach significant difference (P > 0.05). The rate of adverse reaction of 3% (20/70) in study group was significantly lower than 22% (16/73) in control group (P < 0.05).
  
  
  CONCLUSIONS
  it is effective and safe to treat pelvic anaerobic infections with levornidazole and sodium chloride injection.
authors.affiliation: Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Ma
authors.forename: Yuan-Zhen
authors.initials: YZ
authors.lastname: Zhang
authors.forename: Yi-Lin
authors.initials: YL
authors.lastname: Zheng
authors.forename: Ze-Hua
authors.initials: ZH
authors.lastname: Wang
authors.forename: You-di
authors.initials: YD
authors.lastname: Xu
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Kong
mesh_terms: D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009950:Ornidazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D034161:Pelvic Infection / Q000188:drug therapy* / Q000382:microbiology; D012965:Sodium Chloride / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000890:Anti-Infective Agents; D012965:Sodium Chloride; D009950:Ornidazole